COVID-19

Coronavirus disease (COVID-19)

The European Medicines Agency (EMA) is contributing to global efforts to save lives during the COVID-19 pandemic by expediting the development and approval of safe and effective treatments and vaccines, supporting the continued availability of medicines in the European Union (EU), and providing reliable information to patients and healthcare professionals.

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

On 30 January 2020, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern. On 11 March 2020, WHO characterised COVID-19 as a pandemic.

EMA's role during the pandemic

EMA aims to expedite the development of effective medicines and vaccines to fight and prevent the spread of COVID-19.

The Agency also aims to ensure that the assessment and monitoring of medicines are not disrupted so that patients in Europe continue to have access to high quality, safe and effective medicines for all their health needs during the pandemic.

The COVID-19 EMA pandemic Task Force is at the centre of the efforts to enable EMA, the European medicines regulatory network and the European Commission to take quick and coordinated regulatory action during the pandemic across all EU Member States.

EMA is continuously reviewing and adapting its measures as necessary.

In this section

COVID-19: latest updates
Our latest updates on the COVID-19 pandemic, including our news and press releases

COVID-19 vaccines: key facts 
Information on the development and evaluation of safe and effective vaccines for COVID-19

Transparency: exceptional measures for COVID-19 medicines 
Our exceptional measures to maximise the transparency of our regulatory activities on treatments and vaccines for COVID-19 that are approved or are under evaluation

Availability of medicines during COVID-19 pandemic 
EU measures to help prevent and mitigate supply disruptions and medicine shortages during the pandemic

EMA’s governance during COVID-19 pandemic 
Our governance during the COVID-19 pandemic, including the role and activities of the COVID-19 EMA Pandemic Task Force

Treatments and vaccines for COVID-19 
Information on potential treatments and vaccines under investigation, including ongoing clinical trials and observational studies in the EU

COVID-19 vaccines: development, evaluation, approval and monitoring 
Our role in the development, scientific evaluation, approval and monitoring of COVID-19 vaccines in the EU

Guidance for medicine developers and other stakeholders on COVID-19 
Regulatory mechanisms to speed up medicine and vaccine development and approval and advice on clinical trials and regulatory expectations

Public-health advice during COVID-19 pandemic 
Advice for patients and healthcare professionals on the safe use of medicines during the pandemic, in particular in patients with or at risk of COVID-19 infection

Topics

How useful was this page?

Add your rating
Average
34 ratings
5 ratings
2 ratings
1 rating
5 ratings